Ignite Creation Date:
2025-12-25 @ 12:19 AM
Ignite Modification Date:
2026-01-04 @ 4:09 PM
Study NCT ID:
NCT07256158
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-09
First Post:
2025-11-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006689', 'term': 'Hodgkin Disease'}], 'ancestors': [{'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized, Phase III, Non-inferiority study'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 518}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-03-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2033-03-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-02', 'studyFirstSubmitDate': '2025-11-20', 'studyFirstSubmitQcDate': '2025-11-20', 'lastUpdatePostDateStruct': {'date': '2025-12-09', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2033-03-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To evaluate if de-escalated ISRT dose (20 Gy) is not inferior to conventional ISRT dose (30 Gy) in terms of PFS in patients with newly diagnosed early-stage unfavourable HL achieving a complete metabolic response (DS 1-3) after 2 ABVD cycle', 'timeFrame': "From the date of randomization to documented relapse, progression or to the patient's death as a result of any causes (up to 82 months).", 'description': 'Progression-Free Survival (PFS) of the randomized population. Subjects with incomplete follow-up or with no disease evaluation will be censored at the date of last available documented status of freedom from failure.'}], 'secondaryOutcomes': [{'measure': 'To compare OS rates between de-escalated ISRT dose (20 Gy) and conventional ISRT dose (30 Gy) in patients with newly diagnosed early-stage unfavourable HL achieving a complete metabolic response (DS 1-3) after 2 ABVD cycles;', 'timeFrame': 'From the time of randomization to death from any cause (up to 82 months)', 'description': 'Overall Survival (OS) for the randomized population'}, {'measure': 'To evaluate PFS for the whole population', 'timeFrame': 'From the date of consent to documented relapse, progression or death from any cause (up to 84 months)', 'description': 'Progression free survival for the whole enrolled population'}, {'measure': 'To evaluate OS for the whole population', 'timeFrame': 'From the date of consent to death from any cause (up to 84 months)', 'description': 'Overall Survival (OS) for the whole population'}, {'measure': 'To describe pattern of failure "in field", "marginal field", "out of field" relapse after conventional and reduced ISRT;', 'timeFrame': 'From the date of consent to death from any cause (up to 84 months)', 'description': 'Incidence and severity of Adverse Events, graded according to the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v 5.0) during the treatment'}, {'measure': 'To report details on RT treatment volumes and dose distributions and to estimate the dose received by the organs at risk (OARs) in the two treatment arms', 'timeFrame': 'At time of radiotherapy (about 4 months from chemotherapy start)', 'description': 'RT dose received by organs at risk (OARs).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Hodgkin lymphoma', 'Early stage', 'unfavourable', 'untreated', 'ABVD', 'chemotherapy', 'radiotherapy', '20 Gy', '30 Gy', 'randomization', 'PET guided', 'involved site'], 'conditions': ['Hodgkin Lymphoma']}, 'descriptionModule': {'briefSummary': 'The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD.\n\nEarly PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD.\n\nThe aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age ≥18 years;\n* Histologically confirmed classical HL stage I, II unfavorable according to GHSG criteria;\n* Patient with any nodal mass ≥ than 10 cm can be included\n* No previous treatment for Hodgkin lymphoma;\n* ECOG performance status 0 to 2;\n* Presence of FDG-avid lymphoma lesions on baseline PET scan;\n* Subject understands and voluntarily signs the informed consent form approved by the Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures;\n* Adequate organ and marrow function as defined below:\n\n * absolute neutrophil count \\> 1.0 x109/L\n * platelet count \\> 75 x109/L\n * Total bilirubin \\< 2 mg/dl without a pattern consistent with Gilbert\'s syndrome\n * Aspartate Transaminase and Alanine Transaminase (AST/ALT) \\< 3.0 X institutional Upper Limits of Normality (ULN)\n * Creatinine within normal institutional limits or creatinine clearance \\> 50 mL/min\n* Women of childbearing potential must agree to use a highly effective method of contraception (oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device) from the signature of informed consent until six months after the last dose of treatment;\n* Men must agree to use a highly effective method of contraception (barrier contraception or abstinence, when this is in line with the usual lifestyle of the subject) from the signature of informed consent until six months after the last dose of treatment;\n* Women of childbearing potential must have a negative serum pregnancy test at screening.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria are not eligible to enroll:\n* Stage II B- III- IV\n* Hodgkin Lymphoma as "composite lymphoma" or nodular lymphocyte prevalence histological subtype\n* Active HBV and HCV infection\n* HIV seropositivity\n* Pre-treatment with chemotherapy or radiation therapy\n* Malignant disease within the last 5 years (excluding basal skin tumors and carcinoma in situ of the cervix)\n* Women who are pregnant or breast feeding\n* Absence of FDG-avid lymphoma lesions on baseline PET scan\n* Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent.'}, 'identificationModule': {'nctId': 'NCT07256158', 'acronym': 'FIL_PRIORITY', 'briefTitle': 'PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma', 'organization': {'class': 'OTHER', 'fullName': 'Fondazione Italiana Linfomi - ETS'}, 'officialTitle': 'PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma: a Randomized, Phase III, Non-inferiority studY (PRIORITY Study)', 'orgStudyIdInfo': {'id': 'FIL_PRIORITY'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Experimental arm - 20 Gy Radiotherapy', 'description': 'Involved site radiotherapy (ISRT) Total dose of 20 Gy is administered in 10 daily fractions of 2.0 Gy, five times a week over 2 weeks', 'interventionNames': ['Radiation: 20 Gy Involved site radiotherapy']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Comparator arm - 30 Gy Radiotherapy', 'description': 'Involved site radiotherapy (ISRT) Total dose of 30 Gy is administered in 15 daily fractions of 2.0 Gy, five times a week over 3 weeks', 'interventionNames': ['Radiation: 30 Gy Involved site radiotherapy']}], 'interventions': [{'name': '20 Gy Involved site radiotherapy', 'type': 'RADIATION', 'description': 'Total dose 20 Gy Involved site radiotherapy', 'armGroupLabels': ['Experimental arm - 20 Gy Radiotherapy']}, {'name': '30 Gy Involved site radiotherapy', 'type': 'RADIATION', 'description': 'Total dose 30 Gy Involved site radiotherapy', 'armGroupLabels': ['Comparator arm - 30 Gy Radiotherapy']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Alessandria', 'country': 'Italy', 'contacts': [{'name': 'Manuela Zanni, MD', 'role': 'CONTACT', 'email': 'manuela.zanni@ospedale.al.it'}, {'name': 'Manuela Zanni, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia', 'geoPoint': {'lat': 44.90924, 'lon': 8.61007}}, {'city': 'Avellino', 'country': 'Italy', 'contacts': [{'name': 'Sonya De Lorenzo, MD', 'role': 'CONTACT', 'email': 'sonya.delorenzo@aornmoscati.it'}, {'name': 'Sonya De Lorenzo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.R.N. G Moscati - U.O.C. Ematologia e Terapie cellulari avanzate', 'geoPoint': {'lat': 40.91494, 'lon': 14.79103}}, {'city': 'Aviano', 'country': 'Italy', 'contacts': [{'name': 'Michele Spina, MD', 'role': 'CONTACT', 'email': 'mspina@cro.it'}, {'name': 'Michele Spina, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'IRCCS Centro Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlati', 'geoPoint': {'lat': 46.07056, 'lon': 12.59472}}, {'city': 'Bergamo', 'country': 'Italy', 'contacts': [{'name': 'Silvia Ferrari, MD', 'role': 'CONTACT', 'email': 's.ferrari@asst-pg23.it'}, {'name': 'Silvia Ferrari, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'ASST Papa Giovanni XXIII - S.C. Ematologia', 'geoPoint': {'lat': 45.69601, 'lon': 9.66721}}, {'city': 'Bergamo', 'country': 'Italy', 'contacts': [{'name': 'Daniele Laszlo, MD', 'role': 'CONTACT', 'email': 'daniele.laszlo@gavazzeni.it'}, {'name': 'Daniele Laszlo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Clinica Humanitas Gavazzeni - U.O. Oncologia Medica', 'geoPoint': {'lat': 45.69601, 'lon': 9.66721}}, {'city': 'Brescia', 'country': 'Italy', 'contacts': [{'name': 'Chiara Pagani, MD', 'role': 'CONTACT', 'email': 'chiara.pagani@asst-spedalicivili.it'}, {'name': 'Chiara Pagani, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'ASST Spedali Civili - S.C. Ematologia', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'city': 'Cagliari', 'country': 'Italy', 'contacts': [{'name': 'Valeria Oggianu, MD', 'role': 'CONTACT', 'email': 'valeria.oggianu@aob.it'}, {'name': 'Valeria Oggianu, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'ARNAS "Brotzu" P.O. Businco - S.C. Ematologia e TMO', 'geoPoint': {'lat': 39.23054, 'lon': 9.11917}}, {'city': 'Candiolo', 'country': 'Italy', 'contacts': [{'name': 'Umberto Vitolo, MD', 'role': 'CONTACT', 'email': 'umberto.vitolo@ircc.it'}, {'name': 'Umberto Vitolo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'I.R.C.C.S. Istituto di Candiolo - FPO', 'geoPoint': {'lat': 44.95858, 'lon': 7.59812}}, {'city': 'Catania', 'country': 'Italy', 'contacts': [{'name': 'Ugo Consoli, MD', 'role': 'CONTACT', 'email': 'uconsoli@arnasgaribaldi.it'}, {'name': 'Ugo Consoli, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'ARNAS Garibaldi - U.O.C. Ematologia', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'city': 'Cuneo', 'country': 'Italy', 'contacts': [{'name': 'Roberto Sorasio, MD', 'role': 'CONTACT', 'email': 'sorasio.r@ospedale.cuneo.it'}, {'name': 'Roberto Sorasio, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O. S. Croce e Carle - S.C. Ematologia', 'geoPoint': {'lat': 44.39071, 'lon': 7.54828}}, {'city': 'Florence', 'country': 'Italy', 'contacts': [{'name': 'Sabrina Moretti, MD', 'role': 'CONTACT', 'email': 'sabrina.moretti@uslcentro.toscana.it'}, {'name': 'Sabrina Moretti, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.S.L. Toscana Centro - SOC Oncoematologia', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'city': 'Florence', 'country': 'Italy', 'contacts': [{'name': 'Benedetta Puccini, MD', 'role': 'CONTACT', 'email': 'puccinib@aou-careggi.toscana.it'}, {'name': 'Benedetta Puccini, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'city': 'Genova', 'country': 'Italy', 'contacts': [{'name': 'Chiara Ghiggi, MD', 'role': 'CONTACT', 'email': 'chiara.ghiggi@hsanmartino.it'}, {'name': 'Chiara Ghiggi, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'IRCCS Policlinico S. Martino - U.O. Ematologia e terapie cellulari', 'geoPoint': {'lat': 45.21604, 'lon': 11.87211}}, {'city': 'Latina', 'country': 'Italy', 'contacts': [{'name': 'Natalia Cenfra, MD', 'role': 'CONTACT', 'email': 'nataliacenfra81@gmail.com'}, {'name': 'Natalia Cenfra, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'ASL Latina Ospedale S. Maria Goretti - UOC Ematologia con trapianto', 'geoPoint': {'lat': 41.46614, 'lon': 12.9043}}, {'city': 'Milan', 'country': 'Italy', 'contacts': [{'name': 'Vittorio Riggero Zilioli, MD', 'role': 'CONTACT', 'email': 'vittorioruggero.zilioli@ospedaleniguarda.it'}, {'name': 'Vittorio Ruggero Zilioli, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'city': 'Milan', 'country': 'Italy', 'contacts': [{'name': 'Paolo Corradini, MD', 'role': 'CONTACT', 'email': 'paolo.corradini@unimi.it'}, {'name': 'Paolo Corradini, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'IRCCS Fondazione Istituto Nazionale Tumori - S.C. Ematologia', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'city': 'Novara', 'country': 'Italy', 'contacts': [{'name': 'Riccardo Bruna, MD', 'role': 'CONTACT', 'email': 'riccardo.bruna@maggioreosp.novara.it'}, {'name': 'Riccardo Bruna, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U. Ospedale Maggiore della Carità - S.C.D.U. Ematologia', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'city': 'Padua', 'country': 'Italy', 'contacts': [{'name': 'Andrea Visentin, MD', 'role': 'CONTACT', 'email': 'andrea.visentin@aopd.veneto.it'}, {'name': 'Andrea Visentin, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U. di Padova - U.O.C. Ematologia', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'city': 'Padua', 'country': 'Italy', 'contacts': [{'name': 'Dario Marino, MD', 'role': 'CONTACT', 'email': 'dario.marino@iov.veneto.it'}, {'name': 'Dario Marino, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'city': 'Palermo', 'country': 'Italy', 'contacts': [{'name': 'Caterina Patti, MD', 'role': 'CONTACT', 'email': 'k.patti@villasofia.it'}, {'name': 'Caterina Patti, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'city': 'Pavia', 'country': 'Italy', 'contacts': [{'name': 'Manuel Gotti, MD', 'role': 'CONTACT', 'email': 'ma.gotti@smatteo.pv.it'}, {'name': 'Manuel Gotti, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'IRCCS Fondazione Policlinico S. Matteo - S.C. Ematologia 1', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'city': 'Perugia', 'country': 'Italy', 'contacts': [{'name': 'Leonardo Flenghi, MD', 'role': 'CONTACT', 'email': 'leonardo.flenghi@ospedale.perugia.it'}, {'name': 'Leonardo Flenghi, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O. Ospedale S. Maria della Misericordia - Ematologia', 'geoPoint': {'lat': 43.1122, 'lon': 12.38878}}, {'city': 'Piacenza', 'country': 'Italy', 'contacts': [{'name': 'Annalisa Arcari, MD', 'role': 'CONTACT', 'email': 'a.arcari@ausl.pc.it'}, {'name': 'Annalisa Arcari, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AUSL di Piacenza Ospedale Guglielmo da Saliceto - U.O.C. Ematologia e centro trapianti', 'geoPoint': {'lat': 45.05242, 'lon': 9.69342}}, {'city': 'Ravenna', 'country': 'Italy', 'contacts': [{'name': 'Monica Tani, MD', 'role': 'CONTACT', 'email': 'monica.tani@auslromagna.it'}, {'name': 'Monica Tani, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AUSL di Ravenna Osp. S. Maria delle Croci - U.O.C. Ematologia', 'geoPoint': {'lat': 44.41344, 'lon': 12.20121}}, {'city': 'Reggio Emilia', 'country': 'Italy', 'contacts': [{'name': 'Angela Ferrari, MD', 'role': 'CONTACT', 'email': 'ferrari.angela@ausl.re.it'}, {'name': 'Angela Ferrari, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AUSL IRCCS Arcispedale S. Maria Nuova - S.C. Ematologia', 'geoPoint': {'lat': 44.69825, 'lon': 10.63125}}, {'city': 'Roma', 'country': 'Italy', 'contacts': [{'name': 'Ilaria Del Giudice, MD', 'role': 'CONTACT', 'email': 'ilaria.delgiudice@uniroma1.it'}, {'name': 'Ilaria Del Giudice, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U. Policlinico Umberto I - U.O.C Ematologia', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Roma', 'country': 'Italy', 'contacts': [{'name': 'Giacinto La Verde, MD', 'role': 'CONTACT', 'email': 'glaverde@ospedalesantandrea.it'}, {'name': 'Giacinto La Verde, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "A.O.U. Sant'Andrea - U.O.C. Ematologia", 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Roma', 'country': 'Italy', 'contacts': [{'name': 'Luigi Rigacci, MD', 'role': 'CONTACT', 'email': 'l.rigacci@policlinicocampus.it'}, {'name': 'Luigi Rigacci, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fondazione Policlinico Campus Bio-Medico - U.O.C. Ematologia e trapianto di cellule staminali', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Rozzano', 'country': 'Italy', 'contacts': [{'name': 'Francesca Ricci, MD', 'role': 'CONTACT', 'email': 'francesca.ricci@humanitas.it'}, {'name': 'Francesca Ricci, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'IRCCS Humanitas - U.O. Ematologia', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'city': 'San Giovanni Rotondo', 'country': 'Italy', 'contacts': [{'name': 'Angelo Michele Carella, MD', 'role': 'CONTACT', 'email': 'am.carella@operapadrepio.it'}, {'name': 'Angelo Michele Carella, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'IRCCS Fondazione Casa Sollievo della Sofferenza - UOC Ematologia e Trapianto di Cellule Staminali Ematopoietiche', 'geoPoint': {'lat': 41.70643, 'lon': 15.7277}}, {'city': 'Siena', 'country': 'Italy', 'contacts': [{'name': 'Alberto Fabbri, MD', 'role': 'CONTACT', 'email': 'fabbri7@unisi.it'}, {'name': 'Alberto Fabbri, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U. Senese - U.O.C. Ematologia', 'geoPoint': {'lat': 43.31822, 'lon': 11.33064}}, {'city': 'Terni', 'country': 'Italy', 'contacts': [{'name': 'Arcangelo Liso, MD', 'role': 'CONTACT', 'email': 'arcangelo.liso@unipg.it'}, {'name': 'Arcangelo Liso, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O. Santa Maria - S.C. Oncoematologia', 'geoPoint': {'lat': 42.56335, 'lon': 12.64329}}, {'city': 'Torino', 'country': 'Italy', 'contacts': [{'name': 'Candida Vitale, MD', 'role': 'CONTACT', 'email': 'candida.vitale@unito.it'}, {'name': 'Candida Vitale, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U', 'geoPoint': {'lat': 44.88856, 'lon': 11.99138}}, {'city': 'Torino', 'country': 'Italy', 'contacts': [{'name': 'Barbara Botto, MD', 'role': 'CONTACT', 'email': 'bbotto@cittadellasalute.to.it'}, {'name': 'Barbara Botto, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia', 'geoPoint': {'lat': 44.88856, 'lon': 11.99138}}, {'city': 'Treviso', 'country': 'Italy', 'contacts': [{'name': 'Piero Maria Stefani, MD', 'role': 'CONTACT', 'email': 'pieromaria.stefani@aulss2.veneto.it'}, {'name': 'Piero Maria Stefani, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "ULSS 2 Ospedale Ca' Foncello - U.O.C. Ematologia", 'geoPoint': {'lat': 45.66673, 'lon': 12.2416}}, {'city': 'Trieste', 'country': 'Italy', 'contacts': [{'name': 'Francesco Zaja, MD', 'role': 'CONTACT', 'email': 'francesco.zaja@asugi.sanita.fvg.it'}, {'name': 'Francesco Zaja, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.S.U. Giuliano Isontina - S.C. Ematologia', 'geoPoint': {'lat': 45.64953, 'lon': 13.77678}}, {'city': 'Udine', 'country': 'Italy', 'contacts': [{'name': 'Jacopo Olivieri, MD', 'role': 'CONTACT', 'email': 'jacopo.olivieri@asufc.sanita.fvg.it'}, {'name': 'Jacopo Olivieri, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.S.U. Friuli Centrale - Clinica Ematologica', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'city': 'Verona', 'country': 'Italy', 'contacts': [{'name': 'Andrea Bernardelli, MD', 'role': 'CONTACT', 'email': 'andrea.bernardelli@aovr.veneto.it'}, {'name': 'Andrea Bernardelli, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'A.O.U.I. di Verona - U.O.C. Ematologia', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}], 'centralContacts': [{'name': 'Uffici Studi FIL', 'role': 'CONTACT', 'email': 'startup@filinf.it', 'phone': '+390131033153'}, {'name': 'Uffici Studi FIL', 'role': 'CONTACT', 'email': 'gestionestudi@filinf.it', 'phone': '+390599769913'}], 'overallOfficials': [{'name': 'Umberto Ricardi, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'SC Radioterapia U - AOU Città della Salute e della Scienza di Torino'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fondazione Italiana Linfomi - ETS', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}